CVS Health's Aetna unit will pay $117.7 million to resolve federal charges that it knowingly submitted inaccurate diagnosis codes for Medicare Advantage enrollees.
The U.S. Department of Justice announced on Wednesday, March 11, that the civil settlement resolves allegations that Aetna violated the federal False Claims Act by submitting untruthful diagnosis data — including codes for morbid obesity and other health conditions — to the Centers for Medicare & Medicaid Services between 2018 and 2023. The case originated from a January 2024 lawsuit filed in Philadelphia federal court by whistleblower Mary Melette Thomas, a former Aetna risk adjustment coding auditor from Arizona.
According to Yahoo! Finance, the issue has sparked debate about how private insurers interact with government-funded health programs and whether the current Medicare Advantage payment structure invites the very kind of billing irregularities the DOJ is now pursuing. With private insurers receiving more than $530 billion annually from the government to care for Medicare Advantage patients, the financial incentives involved are enormous — and so is the temptation to game the system.
According to the DOJ, Aetna submitted inaccurate diagnosis information to CMS for over five years. Medicare Advantage, also known as Medicare Part C, pays private insurers based in part on the reported health conditions of their enrollees. The sicker the patient population appears on paper, the more the insurer gets paid.
Aetna was also accused of failing to withdraw inaccurate diagnosis codes it uncovered during a review of patients' medical records for 2015. That allegation suggests the company may have been aware of coding problems long before the 2018–2023 period at the center of the settlement. CVS acquired Aetna in 2018, meaning the alleged conduct spans essentially the entirety of CVS's ownership.
The False Claims Act allows whistleblowers to sue on the government's behalf and share in any recoveries. Thomas, the whistleblower who brought the case, will receive $2.01 million from the settlement. Assistant Attorney General Brett Shumate referenced the scale of Medicare Advantage spending in a statement announcing the resolution.
For its part, CVS is not admitting wrongdoing. The company stated that "Aetna continues to disagree with the DOJ's industry-wide allegations, and this settlement should not be seen as an acknowledgment of liability." That language is telling — CVS frames this as an industry-wide issue, not an Aetna-specific one.
CVS Chief Financial Officer Brian Newman described the settlement as part of finding a resolution "regarding a solution that hopefully eliminates any protracted litigation." In other words, it was cheaper to settle than to fight. That's a rational business decision, but it doesn't exactly inspire confidence in the underlying compliance systems. Newman also addressed broader business conditions during recent remarks, characterizing Medicaid cost trends as "stable but elevated, in line with expectations." He described Medicare enrollment heading into 2026 as "flattish but slightly down." On proposed 2027 Medicare rates from CMS, Newman said CVS is "in dialogue with CMS, having conversations."
This settlement doesn't exist in a vacuum. The entire health-insurance sector is under pressure from multiple directions. The Federal Trade Commission in 2024 sued large pharmacy-benefit managers, including CVS Caremark, over drug-pricing practices, and the FTC recently announced a separate settlement with Cigna Group's Express Scripts.
Here's the uncomfortable truth for free-market advocates: Medicare Advantage was supposed to demonstrate that private insurers could deliver Medicare benefits more efficiently than the government. But when the payment model relies on diagnosis codes that insurers themselves report, you've created a system where the entity receiving the money also controls the inputs that determine how much money it receives. That's a structural problem, not just an Aetna problem.
CVS's recent financial results show the company is hardly struggling. Fourth-quarter net income reached $2.92 billion, or $2.30 per share, up from $1.62 billion, or $1.30 per share, a year earlier. Revenue climbed to $105.69 billion from $97.71 billion, and adjusted earnings of $1.09 per share beat the FactSet analyst consensus of $1.00.
CVS kept its 2026 profit guidance unchanged and reaffirmed its earnings-per-share guidance originally issued in December. The $117.7 million settlement, while significant, represents a rounding error on a $105 billion revenue base. For investors, the real question is whether regulatory scrutiny of Medicare Advantage billing practices will intensify across the industry.
For taxpayers, the math is worth pondering. The government pays insurers over $530 billion annually through Medicare Advantage. Even small inaccuracies in diagnosis coding, multiplied across millions of enrollees and dozens of insurers, can translate into billions in overpayments. This settlement recovered $117.7 million — a fraction of what systemic overcoding could cost.
The settlement resolves one case, but the broader questions about Medicare Advantage oversight remain wide open. If Washington is serious about fiscal responsibility, it needs to ensure the incentive structures in programs like Medicare Part C don't reward the very behavior the DOJ is now penalizing. Until then, expect more settlements, more whistleblowers, and more headlines just like this one.